Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis

BACKGROUND: Patients with extensively drug resistant tuberculosis (TB) have limited treatment options with historically poor outcomes. We investigated treatment with 3 oral drugs, bedaquiline (B), pretomanid (Pa) and linezolid (L), (B-Pa-L), with TB bactericidal activity and little pre-existing resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Conradie, Francesca, Diacon, Andreas H, Ngubane, Nosipho, Howell, Pauline, Everitt, Daniel, Crook, Angela M, Mendel, Carl M, Egizi, Erica, Moreira, Joanna, Timm, Juliano, McHugh, Timothy D, Wills, Genevieve, Bateson, Anna, Hunt, Robert, Van Niekerk, Christo, Li, Mengchun, Olugbosi, Morounfolu, Spigelman, Melvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955640/
https://www.ncbi.nlm.nih.gov/pubmed/32130813
http://dx.doi.org/10.1056/NEJMoa1901814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955640/
https://www.ncbi.nlm.nih.gov/pubmed/32130813
http://dx.doi.org/10.1056/NEJMoa1901814

Ejemplares similares